By: Adam Feuerstein | 06/10/14 - 08:36 AM EDT
Talk about uncanny timing, one day after
rips higher on takeover speculation, the company announces the lifting of an FDA clinical hold on its lead hepatitis C drug candidate and the start of a new study with a second hepatitis C compound.
What an amazing coincidence!
Achillion shares are moving 35% higher to $5.75 in Tuesday's premarket. The stock gained 48% to $4.25 on Monday on the back of Merck's (MRK) $3.9 billion acquisition of Idenix Pharmaceuticals (IDIX) to bolster its hepatitis C drug pipeline. The market is betting one of Merck's hepatitis C competitors -- Johnson & Johnson (JNJ), Abbvie (ABBV), Bristol-Myers Squibb (BMY) or Gilead Sciences (GILD) -- will come knocking on Achillion's door.
The FDA lifted a clinical hold on sovaprevir, Achillion's protease inhibitor, to allow higher dosing in hepatitis C patients. Achillion also announced the start of patient dosing in an early study of ACH-3422, a nucleotide polymerase inhibitor. The conventional thinking is that so-called "nucs" are the linchpin of hepatitis C combination therapy. Gilead' Sovaldi is a nuc and will likely generate $9-10 billion in sales this year. Idenix is developing a nuc, which is why Merck acquired the company.
09/16/14 - 01:04 PM EDT
09/15/14 - 10:19 AM EDT
09/12/14 - 09:43 AM EDT
09/11/14 - 01:23 PM EDT
09/10/14 - 03:37 PM EDT
09/18/14 - 09:05 AM EDT
09/17/14 - 12:44 PM EDT
09/17/14 - 09:30 AM EDT
09/16/14 - 12:11 PM EDT
09/15/14 - 10:40 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.